Prof. Martin Steinhoff, Dr. Mahreen Ameen, Dr. Chih-Ho Hong, 20230906000000
Atopic dermatitis (AD) is an inflammatory skin disease with complex aetiology and presentation. Globally, AD incidence is heterogeneous – it is higher in Africa and Oceania and lower in India and northeastern and eastern Europe, said Prof Martin Steinhoff, director, Translational Research Institute, Hamad Medical Corporation in Doha, Qatar, who chaired a Pfizer-sponsored symposium during WCD 2023.
AD has a variable course, and its heterogeneous presentation adds complexity to how the disease is managed. The burden of AD is the highest among all skin diseases, added Steinhoff. It has mental health manifestations such as anxiety and depression, chronic itch, fatigue, skin pain, and sleep disturbance. AD may also co-exist with other comorbidities that could impact patients’ general health. “We need to assess every patient carefully and manage them optimally,” he pointed out.
Steinhoff is joined by renowned experts Dr Mahreen Ameen, consultant dermatologist, Royal Free London NHS Foundation Trust, London, UK, and Dr Chih-Ho Hong, dermatologist, Saint Paul Hospital in Vancouver, Canada. Together, they shared four global cases of AD, including treatment options for patients.
Prof. Johannes Ring, Prof. Sonja Ständer, Prof. Zuotao Zhao, 20230905000000
Atopic dermatitis (AD) is a chronic relapsing skin disease that requires long-term control. At the 25th World Congress of Dermatology (WCD) in Singapore, Professor Sonja Ständer, professor of dermatology and neurodermatology at the University Hospital Münster, Germany, and Professor Zuotao Zhao, dermatologist from the First Hospital, Peking University, Beijing, China, shared clinical approaches to managing patients with moderate-to-severe AD. The session was chaired by Professor Johannes Ring, director, Department of Dermatology and Allergy, Biederstein at the Technical University of Munich, Germany. Among the key topics discussed were the multifactorial nature of AD, its primary symptoms, and the various therapeutic options for itch relief.
Migraine is a debilitating neurological condition that affects millions of people worldwide, causing intense headaches, sensory disturbances, and a significant decline in quality of life. Approximately one-third of patients encounter aura, which encompasses transient focal neurological disturbances that precede the attack. [Lancet 2017;390:1211-1259; Headache 2021;61:1021-1039]
COVID-19 vaccination can reduce the risk of long COVID if given before SARS-CoV-2 infection.
Findings suggest that vaccination before infection confers only partial protection in the post-acute phase of the disease. Hence, reliance on vaccination as a sole mitigation strategy may not optimally reduce long-term health consequences of SARS-CoV-2 infection.
Dr. Paula Ramirez, Prof. Gennaro De Pascale, 20230805000000
In conjunction with the 42nd International Symposium on Intensive Care and Emergency Medicine (ISICEM), Pfizer sponsored a symposium addressing the complex challenges of managing invasive mould disease (IMD) in the intensive care unit (ICU), emphasizing the importance of a proactive mindset among intensivists. Using a real-life patient case study, Dr Paula Ramirez from La Fe University and Polytechnic Hospital, Valencia, Spain highlighted the significance of early suspicion, swift diagnosis, and timely treatment in critically ill patients with IMD. Professor Gennaro De Pascale from the Catholic University of the Sacred Heart, Rome, Italy discussed effective management strategies and the clinical evidence for various antifungals in treating IMD in critically ill patients.
Dengue is endemic in the tropical and sub-tropical regions of the world and afflicts an estimated 100million people each year. The acute infection typically resolves on its own within 7–10 days. In certain instances, however, the infection may lead to longer-term chronic sequelae, which we term here as “long dengue”. Similar post-infectious syndromes have also been observed following other viral infections, such as COVID-19. Among patients with long dengue, chronic fatigue, characterised by persistent fatigue and malaise, is often one of the most prominent symptoms, and can persist for weeks or even months after acute infection. Other potential effects may include concentration impairment, and even depression. The incidence and severity of these chronic sequelae vary between individuals.